CLRB - CIK 0001279704
The table below shows Cellectar Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $11.50M | $26.14M | $27.27M | $18.27M | $17.59M | $10.14M |
| SG&A | $11.48M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $25.64M |
| $11.69M |
| $10.55M |
| $6.54M |
| $5.15M |
| Operating income | -$22.98M | -$51.78M | -$38.96M | -$28.81M | -$24.13M | -$15.29M |
| Income tax | - | $66.00K | -$60.00K | -$60.00K | - | - |
| Net income | -$21.79M | -$44.58M | -$37.98M | -$31.79M | -$24.12M | -$15.09M |
| EPS (diluted) | -$8.35 | -$41.89 | -$3.50 | -$4.51 | -$4.35 | -$1.84 |